Report cover image

Autoimmune Hepatitis Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape

Publisher GlobalData
Published Oct 04, 2022
Length 60 Pages
SKU # GBDT17503837

Description

Autoimmune Hepatitis Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Autoimmune Hepatitis therapeutics.

Synopsis
  • In 2022, there will be more than 36.000 diagnosed incidence cases of Autoimmune Hepatitis across 16 pharmaceutical markets.
  • No FDA-approved marketed drugs are available for Autoimmune Hepatitis. However, there are several treatments used off-label to manage Autoimmune Hepatitis.
  • Among four innovator molecules in the mid- to late-stage pipeline for Autoimmune Hepatitis, only one molecule is in Phase III and the rest are in Phase II.
  • 54% of the clinical trials initiated over the last 10 years for Autoimmune Hepatitis have been conducted in sites across Europe.
  • Deals involving licensing agreements and partnerships for Autoimmune Hepatitis assets are the most common types globally.
  • Innovative therapies for Autoimmune Hepatitis are expected to enter the market no sooner than 2026.
Scope

GlobalData’s Autoimmune Hepatitis: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Retail or Manufacturer Price of Products
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Autoimmune Hepatitis market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Autoimmune Hepatitis market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

60 Pages
  • Report Scope
  • Key Findings
  • Disease Overview
    • Epidemiology Overview: Total Diagnosed Incident Cases of AIH in 2022 and 2027
    • Treatment Guidelines
    • Marketed Drugs – Leading Marketed Drugs in AIH
    • Marketed Drugs – Pricing and Reimbursement
    • Pipeline Drugs Overview – Mid- to Late-Stage Pipeline Drugs in AIH
    • Pipeline Drugs – Overview by Development Stage
    • Pipeline Drugs – Overview by Molecule Type
    • Pipeline Drugs – Overview by Mechanism of Action
    • Pipeline Drugs – Overview by Route of Administration
    • Pipeline Drugs – Drug-Specific Phase Transition Success Rate and Likelihood of Approval in AIH
    • Pipeline Drugs – Phase Transition Success Rates and Likelihood of Approval in Gastrointestinal
    • Clinical Trials in AIH – Historical Overview
    • Clinical Trials in AIH – Overview by Phase
    • Clinical Trials in AIH – Overview by Status
    • Clinical Trials in AIH – Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in AIH – Geographic Overview
    • Clinical Trials in AIH – Single-Country and Multinational Trials by Region
    • Clinical Trials in AIH – Top 20 Sponsors with Breakdown by Phase
    • Clinical Trials in AIH – Top 20 Sponsors with Breakdown by Status
    • Clinical Trials in AIH – Overview by Endpoint Status
    • Clinical Trials in AIH – Enrollment Data
    • Clinical Trials in AIH – Overview of Sites by Geography
    • Clinical Trials in AIH – Top 20 Countries for Trial Sites
    • Clinical Trials in AIH – Top 20 Sites Globally
    • Clinical Trials – Feasibility Analysis: Geography Overview
    • Clinical Trials – Feasibility Analysis: Benchmark Models for AIH
    • Deals Landscape – Mergers, Acquisitions, and Strategic Alliances in AIH by Region
    • Deals Landscape – Recent Mergers, Acquisitions, and Strategic Alliances in AIH
    • Commercial Assessment – Key Market Players in AIH
    • Future Market Catalysts – Upcoming Market Catalysts in AIH
    • Methodology
    • Methodology – Sales Forecasts
    • Methodology – Phase Transition Success Rate and Likelihood of Approval Analysis
    • About the Authors
    • Contact Us – A Global Network of Offices

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us